title: Network pharmacology: reigning in drug attrition?
abstract: In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
authors.affiliation: Department of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, HWCRC, Room 732, MI 48201, USA. mohammar@karmanos.org
authors.forename: Osama M
authors.initials: OM
authors.lastname: Alian
authors.forename: Minjel
authors.initials: M
authors.lastname: Shah
authors.forename: Momin
authors.initials: M
authors.lastname: Mohammad
authors.forename: Ramzi M
authors.initials: RM
authors.lastname: Mohammad
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D017277:Drug Approval / Q000706:statistics & numerical data; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D049490:Systems Biology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor